Literature DB >> 3932353

Biosynthesis of the lysosomal enzyme glucocerebrosidase.

A H Erickson, E I Ginns, J A Barranger.   

Abstract

Multiple biosynthetic forms of glucocerebrosidase were immunoprecipitated after synthesis in vitro using cell-free translation or in vivo using pulse-chase conditions in porcine kidney cells or human fibroblasts. The initial product in vitro was a 52-kDa polypeptide. When canine pancreatic microsomes were present during translation, the nascent polypeptide crossed the microsomal membrane and increased its mass to 60 kDa. Treatment of the 60-kDa polypeptide with endoglycosidase H to remove high mannose carbohydrate yielded a 51-kDa polypeptide. Thus, the membrane-translocated molecule was apparently a high mannose glycoprotein from which a signal peptide had been cleaved, as observed for the lysosomal protease cathepsin D (Erickson, A. H., and Blobel, G. (1979) J. Biol. Chem. 254, 11771-11774). Treatment of pancreatic microsomes or microsomes from porcine kidney cells with protease did not decrease the size of the polypeptide, which shows that this form is not a transmembrane protein bearing a cytoplasmic domain susceptible to digestion. The in vitro product synthesized in the presence of microsomal membranes was indistinguishable from the in vivo product synthesized during pulse-labeling of cultured porcine kidney cells. Following a 2-h chase period, the 60-kDa product was converted to a 59-kDa polypeptide. The major form of glucocerebrosidase detected after a 24-h chase period was a 56-kDa polypeptide, which in turn was converted to a 55-kDa polypeptide by 72 h. The same forms were precipitated from human fibroblasts but the rate of processing was accelerated in this cell type. Limited treatment of the 60-kDa form of glucocerebrosidase with endoglycosidase H suggested that high mannose carbohydrate is added to at least four sites on the polypeptide chain. By 24 h after synthesis, conversion to endoglycosidase H-resistant complex carbohydrate had occurred. Thus, both polypeptide and carbohydrate processing steps are involved in the biosynthesis of glucocerebrosidase.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3932353

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  35 in total

Review 1.  Lessons learned from the development of enzyme therapy for Gaucher disease.

Authors:  J A Barranger; E O'Rourke
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

2.  Histone deacetylase inhibitors prevent the degradation and restore the activity of glucocerebrosidase in Gaucher disease.

Authors:  Jie Lu; Chunzhang Yang; Masako Chen; Donald Y Ye; Russell R Lonser; Roscoe O Brady; Zhengping Zhuang
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-12       Impact factor: 11.205

3.  The studies on substrate, product and inhibitor binding to a wild-type and neuronopathic form of human acid-beta-glucosidase.

Authors:  Igor Z Zubrzycki; Agnieszka Borcz; Magdalena Wiacek; Wojciech Hagner
Journal:  J Mol Model       Date:  2007-08-23       Impact factor: 1.810

Review 4.  The early and late processing of lysosomal enzymes: proteolysis and compartmentation.

Authors:  A Hasilik
Journal:  Experientia       Date:  1992-02-15

5.  Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher disease.

Authors:  Benjamin Liou; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2009-02-13       Impact factor: 4.797

6.  Prediction of response of mutated alpha-galactosidase A to a pharmacological chaperone.

Authors:  Sang H Shin; Stefanie Kluepfel-Stahl; Adele M Cooney; Christine R Kaneski; Jane M Quirk; Raphael Schiffmann; Roscoe O Brady; Gary J Murray
Journal:  Pharmacogenet Genomics       Date:  2008-09       Impact factor: 2.089

Review 7.  GBA-Associated Parkinson's Disease and Other Synucleinopathies.

Authors:  Ziv Gan-Or; Christopher Liong; Roy N Alcalay
Journal:  Curr Neurol Neurosci Rep       Date:  2018-06-08       Impact factor: 5.081

8.  Overexpression of human glucocerebrosidase containing different-sized leaders.

Authors:  M Pasmanik-Chor; O Elroy-Stein; H Aerts; V Agmon; S Gatt; M Horowitz
Journal:  Biochem J       Date:  1996-07-01       Impact factor: 3.857

9.  Genetic heterogeneity in type 1 Gaucher disease: multiple genotypes in Ashkenazic and non-Ashkenazic individuals.

Authors:  S Tsuji; B M Martin; J A Barranger; B K Stubblefield; M E LaMarca; E I Ginns
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

10.  Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies.

Authors:  Joseph R Mazzulli; You-Hai Xu; Ying Sun; Adam L Knight; Pamela J McLean; Guy A Caldwell; Ellen Sidransky; Gregory A Grabowski; Dimitri Krainc
Journal:  Cell       Date:  2011-06-23       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.